Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk
White paper produced by an AstraZeneca sponsored steering committee; committee members received honoraria for their participation.
Lung cancer is one of the most diagnosed cancers in the UK, and it has a profound impact on patients’ lives.2 Emerging evidence suggests that how we support patients before and during treatment could play an important role in patient treatment recovery and outcomes.3-6
An expert panel discussed the evidence alongside first hand clinical experience for providing prehabilitation services to lung cancer patients as early in the diagnostic pathway as possible, to support better patient outcomes.1
Additional authors
Rachael Barlow, Pamela Dalrymple, Asanga Fernando, Kevin Franks, Lucy Gossage, Zoe Merchant Babu Naidu, Andriana Petrova and Cecilia Pompili
GB-74110 | February 2026
GB-74216| DOP : February 2026
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
